Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4C | Q08493 | 3/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.49 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.48 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723616 | 0.94 | PDE4C (0.53) | PDE4CPTGESALOX5GAKRIPK2 | |
| SCHEMBL10267652 | 0.90 | CYP1A1 (0.54) | PDE4CPTGESALOX5CYP1A1CYP1B1 | |
| SCHEMBL723027 | 0.90 | PTGES (0.47) | PDE4CPTGESALOX5GAKRIPK2 | |
| SCHEMBL722839 | 0.87 | PDE4C (0.51) | PDE4CPTGESALOX5CYP1A1CYP1B1 | |
| SCHEMBL723093 | 0.86 | PDE4C (0.55) | PDE4CPTGESALOX5CYP1A1CYP1B1 | |
| SCHEMBL724141 | 0.86 | PDE4C (0.48) | PDE4CPTGESALOX5CYP1A1CYP1B1 | |
| SCHEMBL722312 | 0.86 | JAK2 (0.48) | PDE4CPTGESALOX5CYP1A1CYP1B1 | |
| SCHEMBL723790 | 0.85 | PDE4C (0.47) | PDE4CPTGESALOX5CYP1A1CYP1B1 | |
| SCHEMBL10267530 | 0.85 | KDR (0.50) | PDE4CPTGESALOX5CYP1A1CYP1B1 | |
| SCHEMBL10267552 | 0.84 | PDE4C (0.47) | PDE4CPTGESALOX5CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | claimed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| CN-103052640-A | Furopyridine derivatives | MERCK PATENT GMBH | 2013-04-17 | — | — | CN | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | PDE4C 2858/4885PTGES 2267/4885ALOX5 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.